Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous Close | 1.2500 |
| Open | 1.0400 |
| Bid | 1.0500 x 800 |
| Ask | 1.1300 x 800 |
| Day's Range | 1.0308 - 1.1400 |
| 52 Week Range | 1.0300 - 2.5100 |
| Volume | |
| Avg. Volume | 426,090 |
| Market Cap | 80.648M |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 12.22 |
| EPS (TTM) | 0.0900 |
| Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
Insider MonkeyProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript May 10, 2024 Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business […]
PR NewswireProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
- PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.
